PM

Professor Mattick

Healius Limited | Non-Executive Director
Professor Mattick is a Professor in the School of Biotechnology and Biomolecular Science at UNSW Sydney. From 2018 to 2010, he was Chief Executive of Genomics England, which was established by the UK government to foster the use of genetic information in healthcare. He was Director of the Garvan Institute of Medical Research in Sydney from 2012 to 2018, where he established throughput NATA accredited DNA sequencing and genome analysis facilities. John was a member of the Australian Health Ethics Committee of the National Health & Medical Research Council from 1997 to 2003, an advisor to the Australian Law Reform Commission's Inquiry into the Protection of Human Genetic Information and Gene Patenting & Human Health, and the AHEC Committee to Revise the Ethical Guidelines on Assisted Reproductive Technology. He is a member of the Risk Management Committee.

Company and Role

Company
Title
Tenure
Since
HLS
Healius Limited
  • Non-Executive Director
2yrs, 2mthMar 2022

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
HLS
Healius Limited
14/05/2419,22950,181N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
HLS
Healius Limited
14/05/24
Transfer
15,093$1.340$20,224As advised by the company
HLS
Healius Limited
14/12/23
Issued
7,546$1.200$9,055Rights issue
HLS
Healius Limited
14/12/23
Issued
4,136$1.200$4,963Rights issue
HLS
Healius Limited
04/09/23
Buy
7,547$3.313$25,000Conversion of securities
HLS
Healius Limited
04/09/23
Exercise
7,547$3.313$25,000Conversion of securities